Research Paper Volume 13, Issue 16 pp 20468—20480

The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials


Figure 4. Forest plot of the safety of immune checkpoint inhibitors in treating patients with advanced urothelial cancer. (A) Pooled any-grade adverse events rate. (B) Pooled grade ≥3 adverse events rate. The diamonds represent the pooled indexes. The line crossing the square represents the 95% CI. I2 indicates the heterogeneity in each subgroup meta-analysis. P demonstrates the significance of differences between the subgroups.